Literature DB >> 30250995

Changes in the expression level of IL-17A and p53-fibrinolytic system in smokers with or without COPD.

Mahesh Manjunath Gouda1, Sadiya Bi Shaikh1, Deepu Chengappa2, Irfan Kandhal2, Ashwini Shetty3, Yashodhar Bhandary4.   

Abstract

COPD is a chronic airway inflammatory disease characterized mainly by neutrophil airway infiltrations. The neutrophil airway inflammation is mainly mediated through a key player like the pro-inflammatory cytokine IL-17A which is involved in the modulation of p53-fibrinolytic system. This study was undertaken to examine the molecular changes for the expressions of IL-17A and p53-fibrinolytic system in smokers with or without COPD. Blood and serum samples were collected from ten patients of smokers having COPD and ten samples from smokers without COPD and ten healthy control subjects. Western blot analyses were performed to evaluate the expressions of IL-17A, p53 and PAI-1. Apoptosis was assessed by immunoblot for cleaved caspase-3. In addition, FEV% was also determined of these patients. qRT-PCR was done to detect the gene expression study from the blood samples on p53-fibrinolytic components. A significant difference was found in the expression levels of IL-17A in smokers with COPD patient when compared to smokers without COPD and the control subjects. Similarly the smokers with COPD showed significant increase in the fibrinolytic component PAI-1 as well as in expression levels of p53 when compared to smokers without COPD and normal subjects. Increased cleaved caspase-3 may also promote apoptosis.The expression pattern of the IL-17A in chronic obstructive pulmonary distress syndrome samples was increased as compared of those of normal samples, and their main role in the regulation of and p53-fibrinolytic system makes these components as a predictive prominent component in smokers with COPD.

Entities:  

Keywords:  Chronic obstructive pulmonary disease (COPD); Cigarette smoke; P-p53; P53; Plasminogen activator inhibitor-1 (PAI-I); Urokinase plasminogen activator (uPA); Urokinase plasminogen activator receptor (uPAR)

Mesh:

Substances:

Year:  2018        PMID: 30250995     DOI: 10.1007/s11033-018-4398-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  20 in total

1.  Impact of preventing exacerbations on deterioration of health status in COPD.

Authors:  S Spencer; P M A Calverley; P S Burge; P W Jones
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

2.  Regulation of airway and alveolar epithelial cell apoptosis by p53-Induced plasminogen activator inhibitor-1 during cigarette smoke exposure injury.

Authors:  Shwetha K Shetty; Yashodhar P Bhandary; Amarnath S Marudamuthu; Daniel Abernathy; Thirunavukkarasu Velusamy; Barry Starcher; Sreerama Shetty
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-16       Impact factor: 6.914

Review 3.  Immunologic aspects of chronic obstructive pulmonary disease.

Authors:  Manuel G Cosio; Marina Saetta; Alvar Agusti
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

4.  CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease.

Authors:  M Saetta; A Di Stefano; G Turato; F M Facchini; L Corbino; C E Mapp; P Maestrelli; A Ciaccia; L M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

5.  Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD.

Authors:  W A Biernacki; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

6.  Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study.

Authors:  Dave Singh; Lisa Edwards; Ruth Tal-Singer; Stephen Rennard
Journal:  Respir Res       Date:  2010-06-15

7.  Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD.

Authors:  S Gompertz; D L Bayley; S L Hill; R A Stockley
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

Review 8.  Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema.

Authors:  Ingel K Demedts; Tine Demoor; Ken R Bracke; Guy F Joos; Guy G Brusselle
Journal:  Respir Res       Date:  2006-03-30

9.  Chronic obstructive pulmonary disease (COPD) and occupational exposures.

Authors:  Piera Boschetto; Sonia Quintavalle; Deborah Miotto; Natalina Lo Cascio; Elena Zeni; Cristina E Mapp
Journal:  J Occup Med Toxicol       Date:  2006-06-07       Impact factor: 2.646

Review 10.  Inflammation and immune response in COPD: where do we stand?

Authors:  Nikoletta Rovina; Antonia Koutsoukou; Nikolaos G Koulouris
Journal:  Mediators Inflamm       Date:  2013-07-15       Impact factor: 4.711

View more
  4 in total

1.  A comprehensive network map of IL-17A signaling pathway.

Authors:  D A B Rex; Shobha Dagamajalu; Mahesh Manjunath Gouda; G P Suchitha; Jaikanth Chanderasekaran; Rajesh Raju; T S Keshava Prasad; Yashodhar Prabhakar Bhandary
Journal:  J Cell Commun Signal       Date:  2022-07-15       Impact factor: 5.908

2.  Determining Pharmacological Mechanisms of Chinese Incompatible Herbs Fuzi and Banxia in Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study.

Authors:  Kaiwen Ni; Xiaolu Cai; Yaling Chen; Linshui Zhou; Ruilin Chen; Suqun Zheng; Zhen Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-31       Impact factor: 2.629

Review 3.  Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease?

Authors:  Meiling Liu; Kang Wu; Jinduan Lin; Qingqiang Xie; Yuan Liu; Yin Huang; Jun Zeng; Zhaogang Yang; Yifan Wang; Shiyan Dong; Weiye Deng; Mingming Yang; Song Wu; Wen Jiang; Xuefeng Li
Journal:  Front Pharmacol       Date:  2021-07-02       Impact factor: 5.810

Review 4.  P53 in the impaired lungs.

Authors:  Mohammad A Uddin; Nektarios Barabutis
Journal:  DNA Repair (Amst)       Date:  2020-08-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.